Gluconeogenic Blockade

  • Steven Hochwald
  • Michael Burt
Part of the Medical Intelligence Unit book series (MIU.LANDES)

Abstract

Cancer cachexia is associated with abnormalities in host protein, car bohydrate and fat metabolism. Numerous studies, dating back to 1919, have documented specific alterations in carbohydrate metabolism found in the tumor-bearing state. These alterations can be broadly classified into 1) glucose intolerance and 2) increase in glucose production (gluconeogenesis) and glucose recycling.

Keywords

Placebo Toxicity Glycerol Lactate Neuropathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rohdenburg GL, Bernhard A, Krehbiel O. Sugar tolerance in cancer. JAMA 1919; 72: 1528–1534.CrossRefGoogle Scholar
  2. 2.
    Glicksman AS, Rawson RW. Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer 1956; 9: 1127–1134.PubMedCrossRefGoogle Scholar
  3. 3.
    Marks PA, Bishop JS. The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of intravenous glucose tolerance test. J Clin Invest 1957; 36: 254–264.PubMedCrossRefGoogle Scholar
  4. 4.
    Holroyde CP, Skutches CL, Boden G, Reichard PR. Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 1984; 44: 5910–5913.PubMedGoogle Scholar
  5. 5.
    Norton JA, Maher M, Wesley R, White D, Brennan MF. Glucose intolerance in sarcoma patients. Cancer 1984; 54: 3022–3027.PubMedCrossRefGoogle Scholar
  6. 6.
    Cersosimo E, Pisters PWT, Pesola G et al. The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery 1991; 109: 459–467.PubMedGoogle Scholar
  7. 7.
    Yoshikawa T, Noguchi Y, Matsumoto A. Effects of tumor removal and body weight loss on insulin resistance in patients with cancer. Surgery 1994; 116: 62–66.PubMedGoogle Scholar
  8. 8.
    Castillo M, Scheen A, Lefebvre PJ, Luyckx AS. Insulin-stimulated glucose disposal is not increased in anorexia nervosa. J Clin Endocrinol Metab 1985; 60: 311–314.PubMedCrossRefGoogle Scholar
  9. 9.
    Holroyde CP, Reichard GA. Carbohydrate metabolism in cancer cachexia. Cancer Treat Rep 1981; 65 (Suppl 5): 61–65.Google Scholar
  10. 10.
    Waterhouse C, Kemperman JH. Carbohydrate metabolism in subjects with cancer. Cancer Res 1971; 31: 1273–1278.PubMedGoogle Scholar
  11. 11.
    Long CL, Merrick H, Grecos G, Blakemore WS, Geiger J. Glucose metabolism and colorectal carcinoma. Metabolism 1990; 39 (5): 494–501.PubMedCrossRefGoogle Scholar
  12. 12.
    Shaw JHF, Wolfe RR. Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer: The response to glucose infusion, parenteral feeding, and surgical resection. Surgery 1987; 101 (2): 181–191.PubMedGoogle Scholar
  13. 13.
    Lundholm K, Edstrom S, Karlberg I, Ekman L, Schersten T. Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. Cancer 1982; 50: 1142–1150.PubMedCrossRefGoogle Scholar
  14. 14.
    Reichard GA, Nelson FM, Hochella NJ, Patterson AL, Weinhouse S. Quantitative estimation of the cori cycle in the human. J Biol Chem 1963; 238: 495–501.Google Scholar
  15. 15.
    Eden E, Edstrom S, Bennegard K, Schersten T, Lundholm K. Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res 1984; 44: 1718–1724.PubMedGoogle Scholar
  16. 16.
    Chlebowski RT, Heber D, Richardson B, Block JB. Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. Cancer Res 1984; 44: 857–861.PubMedGoogle Scholar
  17. 17.
    Waterhouse C, Jeanpretre N, Keilson J. Gluconeogenesis from alanine in patients with progressive malignant disease. Cancer Res 1979; 39: 1968–1972.PubMedGoogle Scholar
  18. 18.
    Tayek JA, Bulcavage L, Chlebowski RT. Relationship of hepatic glucose production to growth hormone and severity of malnutrition in a population with colorectal carcinoma. Cancer Res 1990; 50: 2119–2122.PubMedGoogle Scholar
  19. 19.
    Shaw JHF, Humberstone DA, Holdaway C. Weight loss in patients with head and neck cancer:malnutrition or tumour effect. Aust NZ J Surg 1988; 58: 505–509.CrossRefGoogle Scholar
  20. 20.
    Byerley LO, Heber D, Bergman RN, Dubria M, Chi J. Insulin action and metabolism in patients with head and neck cancer. Cancer 1991; 67: 2900–2906.PubMedCrossRefGoogle Scholar
  21. 21.
    Heber D, Byerley LO, Chi J et al. Pathophysiology of malnutrition in the adult cancer patient. Cancer 1986; 58: 1867–1873.PubMedCrossRefGoogle Scholar
  22. 22.
    Shaw JHF, Humberstone DM, Wolfe RR. Energy and protein metabolism in sarcoma patients. Ann Surg 1988; 207 (3): 283–289.PubMedCrossRefGoogle Scholar
  23. 23.
    Heber D, Chlebowski RT, Ishibashi DE, Herrold JN, Block JB. Abnormalities in glucose and protein metabolism in noncachectic lung cancer patients. Cancer Res 1982; 42: 4815–4819.PubMedGoogle Scholar
  24. 24.
    Burt ME, Gorschboth CM, Brennan MF. A controlled, prospective, randomized trial evaluating the metabolic effects of enteral and parenteral nutrition in the cancer patient. Cancer 1982; 49: 1092–1105.PubMedCrossRefGoogle Scholar
  25. 25.
    Norton JA, Burt ME, Brennan MF. In vivo utilization of substrate by human sarcoma-bearing limbs. Cancer 1980; 45: 2934–2939.PubMedCrossRefGoogle Scholar
  26. 26.
    Nolop KB, Rhodes CG, Brudin L et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682–2689.PubMedCrossRefGoogle Scholar
  27. 27.
    Gullino PM, Grantham FH, Courtney AH. Glucose consumption by transplanted tumors in vivo. Cancer Res 1967; 27: 1031–1040.PubMedGoogle Scholar
  28. 28.
    Richtsmeier WJ, Dauchy R, Sauer LA. In vivo nutrient uptake by head and neck cancers. Cancer Res 1987; 47: 5230–5233.PubMedGoogle Scholar
  29. 29.
    Burt ME, Aoki TT, Gorschboth CM, Brennan MF. Peripheral tissue metabolism in cancer-bearing man. Ann Surg 1983; 198: 685–691.PubMedCrossRefGoogle Scholar
  30. 30.
    Lindmark L, Eden E, Terrnell M, Bennegard K, Svaninger G, Lundholm K. Thermic effect and substrate oxidation in response to intravenous nutrition in cancer patients who lose weight. Ann Surg 1986; 204: 628–636.PubMedCrossRefGoogle Scholar
  31. 31.
    Albert JD, Legaspi A, Horowitz GD, Tracey KJ, Brennan MF, Lowry SF. Peripheral tissue metabolism in man with varied disease states and similar weight loss. J Surg Res 1986; 40: 374–381.PubMedCrossRefGoogle Scholar
  32. 32.
    Kallinowski F, Schlenger KH, Runkel S et al. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenographs. Cancer Res 1989; 49: 3759–3764.PubMedGoogle Scholar
  33. 33.
    Macfie J, Burkinshaw L, Oxby C, Holmfield JHM, Hill GL. The effect of gastrointestinal malignancy on resting metabolic expenditure. Br J Surg 1982; 69: 443–446.PubMedCrossRefGoogle Scholar
  34. 34.
    Arbeit JM, Lees DE, Corsey R, Brennan MF. Resting energy expenditure in controls and cancer patients with localized and diffuse disease. Ann Surg 1984; 199 (3): 292–298.PubMedCrossRefGoogle Scholar
  35. 35.
    Peacock JL, Inculet R, Corsey R et al. Resting energy expenditure and body cell mass alterations in noncachectic patients with sarcomas. Surgery 1987; 102 (3): 465–472.PubMedGoogle Scholar
  36. 36.
    Hansell DT, Davies JWL, Burns HJG. The effects on resting energy expenditure of different tumor types. Cancer 1986; 58: 1739–1744.PubMedCrossRefGoogle Scholar
  37. 37.
    Gold J. Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology 1968; 22: 185–207.PubMedCrossRefGoogle Scholar
  38. 38.
    Ray PD, Hanson RL. Inhibition of gluconeogenesis by hydrazine. Fed Proc 1969; 28: 411.Google Scholar
  39. 39.
    Ray PD, Hanson RL, Lardy HA. Inhibition of hydrazine of gluconeogenesis in the rat. J Biol Chem 1970; 245 (4): 690–696.PubMedGoogle Scholar
  40. 40.
    Gold J. Inhibition of Walker 256 intramuscular carcinoma in rats by administration of hydrazine sulfate. Oncology 1971; 25: 66–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Gold J. Inhibition by hydrazine sulfate and various hydrazides of in vivo growth of Walker 256 intramuscular carcinoma, B-16 melanoma, Murphy-Sturm lymphosarcoma and L-1210 solid leukemia. Oncology 1973; 27: 69–80.PubMedCrossRefGoogle Scholar
  42. 42.
    Gold J. Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy. Oncology 1974; 29: 74–89.PubMedCrossRefGoogle Scholar
  43. 43.
    Gold J. Enhancement by hydrazine sulfate of antitumor effectiveness of cytoxan, mitomycin C, methotrexate and bleomycin, in Walker 256 carcinosarcoma in rats. Oncology 1975; 31: 44–53.PubMedCrossRefGoogle Scholar
  44. 44.
    Gold J. Potentiation by clofibrate of in-vivo tumor inhibition by hydrazine sulfate and cytotoxic agents, in Walker 256 carcinosarcoma. Cancer Biochem Biophys 1978; 3: 41–45.PubMedGoogle Scholar
  45. 45.
    Gold J. Use of hydrazine sulfate in advanced cancer patients:preliminary results. Proc Am Ass Canc Res 1974; 15: 83.Google Scholar
  46. 46.
    Gold J. Use of hydrazine sulfate in terminal and preterminal cancer patients:results of investigational new drug (IND) study in 84 evaluable patients. Oncology 1975; 32: 1–10.PubMedCrossRefGoogle Scholar
  47. 47.
    Gershanovich ML, Danova LA, Kondratyev VB et al. Clinical data on the antitumor activity of hydrazine sulfate. Cancer Treat Rep 1976; 60 (7): 933–934.PubMedGoogle Scholar
  48. 48.
    Ochoa M, Wittes RE, Krakoff IH. Trial of hydrazine sulfate (NSC150014) in patients with cancer. Cancer Chemo Rep 1975; 59 (6): 1151–1154.Google Scholar
  49. 49.
    Lerner HJ, Regelson W. Clinical trial of hydrazine sulfate in solid tumors. Cancer Treat Rep 1976; 60 (7): 959–960.PubMedGoogle Scholar
  50. 50.
    Spremulli E, Wampler GL, Regelson W. Clinical study of hydrazine sulfate in advanced cancer patients. Cancer Chemother Pharmacol 1979; 3: 121–124.PubMedCrossRefGoogle Scholar
  51. 51.
    Tayek JA, Heber D, Chlebowski RT. Effect of hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients. Lancet 1987; 2: 241–243.PubMedCrossRefGoogle Scholar
  52. 52.
    Chlebowski RT, Bulcavage L, Grosvenor M et al. Hydrazine sulfate in cancer patients with weight loss. Cancer 1987; 59: 406–410.PubMedCrossRefGoogle Scholar
  53. 53.
    Chlebowski RT, Bulcavage L, Grosvenor M et al. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol 1990; 8 (1): 9–15.PubMedGoogle Scholar
  54. 54.
    Kosty MP, Fleishman SB, Herndon JE et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the cancer and leukemia group B. J Clin Oncol 1994; 12 (6): 1113–1120.PubMedGoogle Scholar
  55. 55.
    Loprinzi CL, Goldberg RM, Su JQ et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994; 12 (6): 1126–1129.PubMedGoogle Scholar
  56. 56.
    Loprinzi CL, Kuross SA, O’Fallon JR et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994; 12 (6): 1121–1125.PubMedGoogle Scholar
  57. 57.
    Ditullio NW, Berkoff CE, Blank B, Kostos V, Stack EJ, Saunders HL. 3-Mercaptopicolinic acid, an inhibitor of gluconeogenesis. Biochem J 1974; 138: 387–394.PubMedGoogle Scholar
  58. 58.
    Kostos V, Ditullio NW, Rush J, Cieslinski L, Saunders HL. The effect of 3-mercaptopicolinic acid on phosphoenolpyruvate carboxykinase (GTP) in the rat and guinea pig. Arch Biochem Biophys 1975; 171: 459–465.PubMedCrossRefGoogle Scholar
  59. 59.
    Burt ME, Lowry SF, Gorschboth C, Brennan MF. Metabolic alterations in a noncachectic animal tumor system. Cancer 1981; 47: 26–34.Google Scholar
  60. 60.
    Blank B, Ditullio NW, Deviney L, Roberts JT, Saunders HL. Synthesis and hypoglycemic activity of S-acyl derivatives of 3-mercaptopicolinic acid. J Med Chem 1977; 20 (4): 577–579.PubMedCrossRefGoogle Scholar
  61. 61.
    Watford M, Vinay P, Lemieux G, Gougoux A. Inhibition of renal gluconeogenesis and phosphoenolpyruvate carboxykinase activity by 3-mercaptopicolinic acid:studies in rat, guinea pig, dog, rabbit, and man. Can J Biochem 1980; 58: 440–445.PubMedCrossRefGoogle Scholar
  62. 62.
    Burt ME, Brennan MF. Unpublished observations 1980.Google Scholar
  63. 63.
    Anonymous investigational drug number 9603 on 3-mercaptopicolinic acid (Smith, Kline and French 34288). Food and Drug Administration 1973.Google Scholar
  64. 64.
    Burt ME, Peters ML, Brennan MF. Hypoglycemia with glycerol infusion as antineoplastic therapy:a hypothesis. Surgery 1985; 97 (2): 231–233.PubMedGoogle Scholar
  65. 65.
    Linn ECC. Glycerol utilization and its regulation in mammals. Ann Rev Biochem 1977; 46: 66–95.Google Scholar
  66. 66.
    Harding JW, Pyeritz EA, Morr HP. Proportional activities of glycerol kinase and glycerol-3-phosphate dehydrogenase in rat hepatomas. Biochem J 1975; 148: 545–550.PubMedGoogle Scholar
  67. 67.
    Burt ME. Metabolic alterations in a methylcholanthrene-induced rat sarcoma. Dissert Abstracts Internat 1981; 41: 4399B - 4400B.Google Scholar
  68. 68.
    Sloviter HA, Shimkin P, Suhara K. Glycerol as a substrate for brain metabolism. Nature 1966; 210: 1334–1336.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Steven Hochwald
  • Michael Burt

There are no affiliations available

Personalised recommendations